Brazil Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Brazil Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Brazil Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The current state of political uncertainty will not shake Brazil's leading position as Latin America's largest pharmaceutical and healthcare market. The Brazilian government has been committed to improving the population's access to healthcare for decades. Having said this , Brazil's private healthcare market will experience contraction in real terms in 2016 due to the deteriorating political and economic outlook.

Headline Expenditure Projections

Pharmaceuticals: BRL66.8bn (USD20.0bn) in 2015 to BRL71.7bn (USD17.9bn) in 2016; +7.4% in local currency terms and -10.6% in US dollar terms. Forecast in local currency terms has been revised downward from Q 216.

Healthcare: BRL568.3bn (USD170.6bn) in 2015 to BRL619.8bn (USD155.0bn) in 2016; +9.1% in local currency terms and -9.2% in US dollar terms . Forecast in local currency terms has been revised downward from Q 216 .

Headline Pharmaceuticals & Healthcare Forecasts (Brazil 2014-2020)
2014 2015e 2016f 2017f 2018f 2019f 2020f
e/f = BMI estimate/forecast. Source: The Brazilian Pharmaceutical Industry Federation (Febrafarma), Group of Executives of the Pharmaceutical Market (Grupemef), Interfarma, World Health Organization (WHO), BMI
Pharmaceutical sales, USDbn 26.346 20.048 17.933 18.775 21.681 24.543 22.943
Pharmaceutical sales, % of GDP 1.09 1.13 1.15 1.15 1.15 1.13 1.11
Pharmaceutical sales, % of health expenditure 11.9 11.8 11.6 11.5 11.4 11.3 11.1
Health spending, USDbn 220.551 170.588 154.961 163.489 190.620 218.078 205.765

Risk/Reward Index

Brazil scores 62.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Index (RRI), making it the fourth-most attractive pharmaceutical market in the Americas this quarter. We highlight that Brazil will continue to be the most important market for multinationals in Latin America. Its position has been very well reflected in this quarter's RRI scores, primarily a result of the country's consistent economic growth and the government's commitment to promoting local industry.

Latest Updates

  • In March 2016, Brazil's Chamber of Deputies voted in favour of increasing federal healthcare expenditure by BRL140bn (USD38bn) by 2023. The proposal suggested to increase the minimum mandatory healthcare spending from 13% of current net revenue to 19.4% by 2023 (14.8% in 2017, 15.5% in 2018, 16.2% in 2019, 16.9% in 2020, 17.6% in 2021, 18.3% in 2022 and 19.4% in 2023).

  • In March 2016, the federal government promised to invest BRL649.1mn (USD176mn) over the next four years in research on the Zika virus and microcephaly. The investment will fund the development of diagnostic tests and vaccines, innovation in health service management and strategies to combat Aedes aegypti, the mosquito that transmits Zika, as well as dengue and chikungunya.

  • On March 31 2016, Brazil's Ministry of Health delayed the publication of the guide adjustment for medicine prices.

  • In February 2016, the board of Brazil's National Economic Development Bank (BNDES - Banco Nacional de Desenvolvimento Economico) approved BRL401mn (USD103mn) in funding for the construction of two biopharmaceutical production sites.

  • In February, the Brazilian government extended the validity of prescriptions for treating hypertension, diabetes and asthma in the People's Pharmacy program.

  • In February, 12 states in Brazil decided to raise the rate of Tax on Goods and Services (ICMS) on medicines.

  • In January, the Brazilian drugmaker, Hypermarcas, agreed to the sale of its contraception division to Britain's Reckitt Benckiser for BRL675mn (USD169mn).

BMI Economic View

Brazil's recession will deepen in 2016 as the labour market experiences significant deterioration as corporate bankruptcies rise. Household spending will fall significantly as the unemployment rate increases, boosting the country's default rate and sending real wages lower.

BMI Political View

President Dilma Rousseff will stave off impeachment by accommodating policies endorsed by the more left-leaning members of her party. However, this will preclude many fiscal austerity measures proposed by the government in its attempt to limit economic stagnation.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Brazil 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Brazil 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020)
25
OTC Medicine Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Brazil 2012-2020)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Brazil 2014-2020)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (Brazil 2014-2020)
30
Industry Risk/Reward Index
31
Americas Risk/Reward Index
31
Brazil Risk/Reward Index
37
Rewards
37
Risks
37
Regulatory Review
39
Intellectual Property Issues
40
Pricing Regime
43
Reimbursement Regime
44
Market Overview
47
Healthcare Sector
48
Table: Healthcare Resources (Brazil 2010-2015)
49
Table: Healthcare Personnel (Brazil 2010-2015)
49
Table: Healthcare Activity (Brazil 2010-2015)
50
Research & Development
50
Biotechnology
52
Clinical Trials
53
Epidemiology
54
Competitive Landscape
57
Research-Based Industry
57
Table: Top 10 Pharmaceutical Companies In Brazil By Sales In 2013
57
Table: Multinational Pharmaceutical Company Activity
58
Generic Drugmakers
58
Pharmaceutical Distribution
61
Pharmaceutical Retail Sector
63
Company Profile
65
Ach-/Biosint-tica
65
Crist-lia
69
EMS Sigma
72
Eurofarma
75
GlaxoSmithKline
77
Table: GlaxoSMITHKLINE'S Strong Collaborative Efforts In Public-Private Partnerships (Ppps) In Brazil
79
Medley
81
Merck & Co
83
Novartis
86
Pfizer
89
Roche
92
Sanofi
95
Demographic Forecast
98
Table: Population Headline Indicators (Brazil 1990-2025)
99
Table: Key Population Ratios (Brazil 1990-2025)
99
Table: Urban/Rural Population & Life Expectancy (Brazil 1990-2025)
100
Table: Population By Age Group (Brazil 1990-2025)
100
Table: Population By Age Group % (Brazil 1990-2025)
101
Glossary
103
Methodology
105
Pharmaceutical Expenditure Forecast Model
105
Healthcare Expenditure Forecast Model
105
Notes On Methodology
106
Risk/Reward Index Methodology
107
Index Overview
108
Table: Pharmaceutical Risk/Reward Index Indicators
108
Indicator Weightings
109

The Brazil Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Brazil Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Brazil pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Brazil, to test other views - a key input for successful budgeting and strategic business planning in the Brazilian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Brazilian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Brazil.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.